Showing 1 - 4 results of 4 for search 'Sebastian Meerwein', query time: 0.02s Refine Results
  1. 1
    Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND

    Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND by Ronald F van Vollenhoven, Roy Fleischmann, Stephen Hall, Yanna Song, Sebastian Meerwein, Alvin F Wells, Oishi Tanjinatus

    Published 2024-07-01
    Get full text
    Article
  2. 2
    Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

    Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biolo... by Vibeke Strand, Michael Schiff, Namita Tundia, Alan Friedman, Sebastian Meerwein, Aileen Pangan, Arijit Ganguli, Mahesh Fuldeore, Yan Song, Janet Pope

    Published 2019-12-01
    Get full text
    Article
  3. 3
    Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

    Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE) by Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Masayuki Yokoyama, Aileen L. Pangan, Yuko Konishi, Sebastian Meerwein, Yoshiya Tanaka

    Published 2021-01-01
    Get full text
    Article
  4. 4
    Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

    Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-B... by Roy Fleischmann, Stephen Hall, Bernard Combe, Andrea Rubbert-Roth, Christina Charles-Schoeman, Nasser Khan, Heidi S Camp, Sebastian Meerwein, Kyle M Carter

    Published 2024-07-01
    Get full text
    Article

Search Tools: